CN107949425A - 用于治疗癌症的包含泊马度胺和抗cs1抗体的免疫治疗给药方案 - Google Patents

用于治疗癌症的包含泊马度胺和抗cs1抗体的免疫治疗给药方案 Download PDF

Info

Publication number
CN107949425A
CN107949425A CN201680049473.8A CN201680049473A CN107949425A CN 107949425 A CN107949425 A CN 107949425A CN 201680049473 A CN201680049473 A CN 201680049473A CN 107949425 A CN107949425 A CN 107949425A
Authority
CN
China
Prior art keywords
pomalidomide
dexamethasone
antibody
dose
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680049473.8A
Other languages
English (en)
Chinese (zh)
Inventor
C·L·马利根
J·B·巴特利特
M·D·罗宾斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN107949425A publication Critical patent/CN107949425A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201680049473.8A 2015-06-29 2016-06-28 用于治疗癌症的包含泊马度胺和抗cs1抗体的免疫治疗给药方案 Pending CN107949425A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562185968P 2015-06-29 2015-06-29
US62/185,968 2015-06-29
US201562239965P 2015-10-11 2015-10-11
US62/239,965 2015-10-11
US201562262574P 2015-12-03 2015-12-03
US62/262,574 2015-12-03
PCT/US2016/039723 WO2017003990A1 (en) 2015-06-29 2016-06-28 Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer

Publications (1)

Publication Number Publication Date
CN107949425A true CN107949425A (zh) 2018-04-20

Family

ID=56409706

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680049473.8A Pending CN107949425A (zh) 2015-06-29 2016-06-28 用于治疗癌症的包含泊马度胺和抗cs1抗体的免疫治疗给药方案

Country Status (20)

Country Link
US (2) US10925867B2 (enExample)
EP (2) EP3313528B1 (enExample)
JP (1) JP6754785B2 (enExample)
CN (1) CN107949425A (enExample)
BR (1) BR112017027692A2 (enExample)
CA (1) CA2990478A1 (enExample)
CY (1) CY1124543T1 (enExample)
DK (1) DK3313528T3 (enExample)
EA (1) EA035888B1 (enExample)
ES (1) ES2886657T3 (enExample)
HR (1) HRP20211478T1 (enExample)
HU (1) HUE056491T2 (enExample)
LT (1) LT3313528T (enExample)
MX (1) MX391581B (enExample)
PL (1) PL3313528T3 (enExample)
PT (1) PT3313528T (enExample)
RS (1) RS62352B1 (enExample)
SI (1) SI3313528T1 (enExample)
SM (1) SMT202100567T1 (enExample)
WO (1) WO2017003990A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3925609B1 (en) * 2014-08-22 2025-07-30 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
PL3313528T3 (pl) * 2015-06-29 2021-12-13 Bristol-Myers Squibb Company Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534860A (zh) * 2006-08-07 2009-09-16 Pdl生物制药公司 使用抗cs1-抗体治疗多发性骨髓瘤的组合物和方法
CN101686971A (zh) * 2006-08-07 2010-03-31 菲赛特生物技术公司 使用基于抗cs1-抗体的联合疗法治疗多发性骨髓瘤的方法
CN102302494A (zh) * 2002-05-17 2012-01-04 细胞基因公司 使用4-(氨基)-2-(2,6-二氧代(3-(哌啶基))-异二氢吲哚-1,3-二酮用于治疗和控制淀粉样病变的方法及组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA204125A (en) 1920-09-21 Sylvester Pratt Edwin Gramophone operated toy
US819826A (en) 1905-12-14 1906-05-08 Frank R Welcher Stanchion.
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
SI2112166T1 (sl) 1998-12-23 2019-05-31 Pfizer Inc. Človeška monoklonska protitelesa proti CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
SK287200B6 (sk) 1999-02-22 2010-03-08 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US6958115B2 (en) 2003-06-24 2005-10-25 The United States Of America As Represented By The Secretary Of The Navy Low temperature refining and formation of refractory metals
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA2660102C (en) * 2006-08-07 2017-02-21 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
WO2008019379A2 (en) 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
US8603477B2 (en) 2008-10-31 2013-12-10 Abbvie Biotherapeutics Inc. Use of anti-CS1 antibodies for treatment of rare lymphomas
EP3351240B1 (en) 2009-05-19 2019-04-10 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
WO2011053322A1 (en) 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
US20130052158A1 (en) 2009-10-30 2013-02-28 University Of Arkansas For Medical Science Use of autologous effector cells for treatment of multiple myeloma
US9506481B1 (en) 2013-01-31 2016-11-29 Daniel Theobald High force hydraulic actuator
HK1232121A1 (zh) * 2014-01-13 2018-01-05 University Of Central Florida Research Foundation, Inc. 作为抗氧化治疗的富勒烯化合物
EP3925609B1 (en) * 2014-08-22 2025-07-30 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US10011657B2 (en) 2014-10-31 2018-07-03 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
PL3313528T3 (pl) * 2015-06-29 2021-12-13 Bristol-Myers Squibb Company Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102302494A (zh) * 2002-05-17 2012-01-04 细胞基因公司 使用4-(氨基)-2-(2,6-二氧代(3-(哌啶基))-异二氢吲哚-1,3-二酮用于治疗和控制淀粉样病变的方法及组合物
CN101534860A (zh) * 2006-08-07 2009-09-16 Pdl生物制药公司 使用抗cs1-抗体治疗多发性骨髓瘤的组合物和方法
CN101686971A (zh) * 2006-08-07 2010-03-31 菲赛特生物技术公司 使用基于抗cs1-抗体的联合疗法治疗多发性骨髓瘤的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRITS VAN RHEE等: "Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma", 《MOLECULAR CANCER THERAPY》 *
ZAHRA HANAIZI等: "The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use", 《ONCOLOGIST》 *

Also Published As

Publication number Publication date
ES2886657T3 (es) 2021-12-20
BR112017027692A2 (pt) 2018-10-09
DK3313528T3 (da) 2021-09-20
PL3313528T3 (pl) 2021-12-13
US10925867B2 (en) 2021-02-23
MX2017015765A (es) 2018-04-13
PT3313528T (pt) 2021-09-16
JP6754785B2 (ja) 2020-09-16
US20210154183A1 (en) 2021-05-27
JP2018522881A (ja) 2018-08-16
LT3313528T (lt) 2021-10-11
MX391581B (es) 2025-03-04
SMT202100567T1 (it) 2021-11-12
WO2017003990A1 (en) 2017-01-05
EP3950065A1 (en) 2022-02-09
CA2990478A1 (en) 2017-01-05
EA201890035A1 (ru) 2018-06-29
EP3313528A1 (en) 2018-05-02
HRP20211478T1 (hr) 2021-12-24
RS62352B1 (sr) 2021-10-29
EP3313528B1 (en) 2021-08-04
SI3313528T1 (sl) 2021-11-30
EA035888B1 (ru) 2020-08-27
CY1124543T1 (el) 2022-07-22
US20180185348A1 (en) 2018-07-05
HUE056491T2 (hu) 2022-02-28

Similar Documents

Publication Publication Date Title
JP2022115924A (ja) グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
US20130064831A1 (en) Immunotherapeutic dosing regimens and combinations thereof
CN115350263A (zh) 谷氨酸调节剂与免疫疗法用以治疗癌症的用途
KR20190120792A (ko) 폐암의 치료를 위한 항-pd-1 항체
US20160264670A1 (en) Immunotherapeutic dosing regimens and combinations thereof
KR20110013423A (ko) 보조자극 경로의 조절에 대한 환자 반응을 예측하는 방법
CN108969763A (zh) 通过破坏pd-1/pd-l1信号传输的免疫治疗
US20210154183A1 (en) Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
US20170355768A1 (en) Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
CN116744976A (zh) 用于治疗实体癌的her3放射免疫疗法
US20220143228A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
US11040223B2 (en) Compositions and methods related to xCT peptides
US20230248855A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
KR20230128271A (ko) 고형 암의 치료를 위한 her3 방사선면역요법
US20250205375A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
EP4637821A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180420

RJ01 Rejection of invention patent application after publication